Feb. 5, 2024—Beckman Coulter Diagnostics unveiled its DxC 500 AU chemistry analyzer today at Medlab Middle East in Dubai.
Read More »Beckman joins forces with Johns Hopkins
November 2018—Beckman Coulter Diagnostics is collaborating with Johns Hopkins Medicine to explore co-innovation initiatives with the goal of developing and commercializing novel solutions that address challenges in health care.
Read More »Beckman Coulter joins forces with Johns Hopkins
Oct. 18, 2018—Beckman Coulter Diagnostics is collaborating with Johns Hopkins Medicine to explore co-innovation initiatives with the goal of developing and commercializing novel solutions that address challenges in health care.
Read More »Beckman introduces Access Sensitive Estradiol
June 2018—Beckman Coulter Diagnostics launched its Access Sensitive Estradiol in the U.S. and in the majority of worldwide markets. The assay aims to help laboratories deliver more accurate results for patients seeking answers to reproductive health questions.
Read More »Beckman Coulter adds 6-AM and BUP assays, 4/18
April 2018—Beckman Coulter Diagnostics announced the addition of 6-acetylmorphine and buprenorphine assays to its menu of drugs-of-abuse tests for use on its AU chemistry analyzers (AU480, AU680, AU5800). The Syva Emit II Plus 6-AM assay provides a convenient and quick way to selectively screen for heroin use, in place of methods such as gas chromatography and mass spectrometry.
Read More »Beckman introduces Access Sensitive Estradiol
April 11, 2018—Beckman Coulter Diagnostics announced the launch of its Access Sensitive Estradiol assay in the U.S. and in a majority of markets worldwide. The test is commonly ordered for detecting estradiol levels in women, children, and men. The assay aims to help laboratories deliver more accurate results for patients seeking answers to reproductive health questions. It has a broad ...
Read More »FDA-cleared Access AMH immunoassay, 3/18
March 2018—Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic use. This test aids health care providers in the assessment of a woman’s ovarian reserve and helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life.
Read More »Beckman enhances Access 2 system, 12/17
December 2017—Beckman Coulter Diagnostics announced its Access 2 immunoassay system is available with enhanced features that aim to improve ease of use, workflow efficiencies, system reliability, and customer satisfaction.
Read More »Access hsTnI assay gets CE mark, 12/17
November 2017—Beckman Coulter Diagnostics received CE mark clearance for a high-sensitivity troponin assay that aids in diagnosing myocardial infarction for patients presenting with chest pain or other ischemic symptoms.
Read More »Beckman Coulter adds PCT assay, 10/17
October 2017—Beckman Coulter Diagnostics and partner Diazyme Laboratories announced FDA clearance of a new procalcitonin (PCT) assay for the management of bacterial infections and sepsis.
Read More »Pancreatic amylase assay, 9/16
September 2016—Beckman Coulter released the Sentinel Pancreatic Amylase reagent and calibrator, a barcoded, ready-to-use liquid reagent distributed by Beckman Coulter and manufactured by Milan-based Sentinel Diagnostics.
Read More »Thyroid stimulating hormone assay, 3/16
March 2016—Beckman Coulter Diagnostics obtained a CE mark for and released its new Access TSH (3rd IS) assay for use with the company’s Access family of immunoassay systems. This assay is the next generation of the Access Hypersensitive hTSH and Access Fast hTSH assays for the quantitative determination of human thyroid stimulating hormone (TSH, thyrotropin) levels in human serum and plasma.
Read More »